spatial

By Targets:	Amyloid-β (2) Apoptosis (3) Autophagy (2) Biochemical Assay Reagents (1) Cholinesterase (ChE) (2) DNA Stain (1) Drug Metabolite (1) Epigenetic Reader Domain (1) GABA Receptor (2) iGluR (4) Keap1-Nrf2 (1) mGluR (1) MMP (2) NO Synthase (1) Notch (2) Organoid (2) p38 MAPK (2) Phosphodiesterase (PDE) (1) PKA (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (3) Neurological Disease (11)
Click Chemistry:	Alkynes (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-139912

Biotin-aniline	DNA Stain	Others
Biotin-aniline is a probe with substantially high reactivity towards RNA and DNA. Biotin-aniline emerges as more efficient probe for capturing subcellular transcriptome in living cells with high spatial specificity .

HY-136611

ω-Hydroxy-DEET	Drug Metabolite	Infection
ω-Hydroxy-DEET is a major metabolite of insect repellent N-N-diethyl-meta-toluamide (DEET). ω-Hydroxy-DEET has anti-proliferative effects. DEET is a spatial repellent and an irritant that commonly used to prevent contact with mosquitoes .

HY-P2259

TAT-GluA2 3Y	iGluR	Neurological Disease
TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .

HY-100406

(S)-MCPG 1 Publications Verification (+)-MCPG	mGluR	Neurological Disease
(S)-MCPG ((+)-MCPG) is a potent group I/II metabotropic glutamate receptor (mGluRs) antagonist and the active isomer of (RS)-MCPG (HY-100371) . (S)-MCPG can be used for the study of the function of mGluRs in spatial learning .

HY-103530

CGP35348	GABA Receptor	Neurological Disease
CGP 35348 is a selective, brain penetrant, centrally active GABAB receptor antagonist with an EC₅₀ of 34 μM. CGP 35348 shows affinity for the GABAB receptor only . CGP 35348 has a potential to improve neuromuscular coordination and spatial learning in albino mouse following neonatal brain damage .

HY-120782

Yhhu-3792	Notch	Neurological Disease
Yhhu-3792 enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 increases the spatial and episodic memory abilities of mice. Yhhu-3792 has the potential for the research of impairment of learning and memory associated DG dysfunction .

HY-120782A

Yhhu-3792 hydrochloride	Notch	Neurological Disease
Yhhu-3792 hydrochloride enhances the self-renewal capability of neural stem cells (NSCs). Yhhu-3792 hydrochloride activates Notch signaling pathway and promotes the expression of Hes3 and Hes5. Yhhu-3792 hydrochloride expands the NSCs pool and promotes endogenous neurogenesis in the hippocampal dentate gyrus (DG) in mouse. Yhhu-3792 hydrochloride increases the spatial and episodic memory abilities of mice. Yhhu-3792 hydrochloride has the potential for the research of impairment of learning and memory associated DG dysfunction .

HY-N0204

Pulchinenoside A Anemoside A3	iGluR	Others
Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.

HY-P2004

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-P2004A

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-103510

TB-21007	GABA Receptor	Neurological Disease
TB-21007 is an inverse agonist of α₅β₃γ₂ subunit-containing GABA_A receptor with a K_i of 1.6 nM. TB-21007 enhanced spatial memory in rats .

HY-125232

MS645	Epigenetic Reader Domain	Cancer
MS645 is a bivalent BET bromodomains (BrD) inhibitor with a K_i of 18.4 nM for BRD4-BD1/BD2. MS645 spatially constrains bivalent inhibition of BRD4 BrDs resulting in a sustained repression of BRD4 transcriptional activity in solid-tumor cells .

HY-18730

1400W W1400
1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-155572

Nrf2 activator-8	Keap1-Nrf2	Inflammation/Immunology
Nrf2 activator-8 (compound 10e) is a Nrf2 activator (EC₅₀=37.9 nM). Nrf2 activator-8 exhibits remarkable antioxidant and anti-inflammatory effects in BV-2 microglial cells. Nrf2 activator-8 can significantly restore spatial memory deficits in a mouse model of lipopolysaccharide (LPS)-induced neuroinflammation .

HY-18731

1400W Dihydrochloride 10+ Cited Publications	NO Synthase Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
1400W dihydrochloride is the dihydrochloride form of 1400W (HY-18731). 1400W is a slow, tight binding, and highly selective inducible nitric-oxide synthase (iNOS) inhibitor, with a K_d value ≤ 7 nM. 1400W inhibits iNOS induction in microglial cells, and reduces generation of NO, thereby mitigating oxidative stress and neuronal cell apoptosis in the rat cerebral cortex, and improving the spatial memory dysfunction caused by acute hypobaric hypoxia-reoxygenation .

HY-10295

SB 202190 Maximum Cited Publications 80 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .

HY-10295A

SB 202190 hydrochloride Maximum Cited Publications 80 Publications Verification	Organoid p38 MAPK Autophagy Apoptosis	Neurological Disease Cancer
SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC₅₀s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a K_d of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .

HY-131885

RuBi-Glutamate hexafluorophosphate sodium	Others	Neurological Disease
RuBi-Glutamate hexafluorophosphate sodium is a novel cage glutamate compound based on ruthenium photochemistry. RuBi-Glutamate hexafluorophosphate sodium can be excited at visible wavelengths and release glutamate after single or two-photon excitation. It has high quantum efficiency and can be used at low concentrations, partially avoiding the blocking of GABA energy transmission by other cage compounds. Two-photon release of RuBi-Glutamate hexafluorophosphate sodium has high spatial resolution and produces a physiodynamic excitatory response in a single dendritic spine .

HY-D0175

3-Aminopropyltriethoxysilane γ-Aminopropyltriethoxysilane; APTES	Biochemical Assay Reagents	Others
3-Aminopropyltriethoxysilane (APTES) acts as a strong glue to immobilize biomolecules such as antibodies and enzymes to silicon and silicon derivatives such as silicon nitride (Si₃N₄)) on. 3-Aminopropyltriethoxysilane also acts as a spacer, providing biomolecules with more spatial freedom during immobilization for higher specific activity. 3-Aminopropyltriethoxysilane can form a more stable, sensitive, and highly biocompatible bioanalytical platform by immobilizing biomolecules onto some solid materials, electrode materials, nanomaterials, and nanocomposites .

HY-B0764

Bucladesine sodium 20+ Cited Publications Dibutyryl cAMP sodium salt; DBcAMP sodium salt	PKA Phosphodiesterase (PDE)	Inflammation/Immunology
Bucladesine sodium salt (Dibutyryl-cAMP sodium salt) is a stabilized cyclic AMP (cAMP) analog and a selective PKA activator. Bucladesine sodium salt raises the intracellular levels of cAMP. Bucladesine sodium salt is also a phosphodiesterase (PDE) inhibitor. Bucladesine sodium salt has anti-inflammatory activity and can be used for impaired wound healing .

HY-155733

AChE/Aβ-IN-1	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-1 (compound 32) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with an IC₅₀ of 86 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 3.876 μM. AChE/Aβ-IN-1 also inhibits Aβ aggregation and shows good blood-brain barrier permeability and neuroprotection. AChE/Aβ-IN-1 improves cognitive and spatial memory impairment in rats model .

HY-155735

AChE/Aβ-IN-2	iGluR Cholinesterase (ChE) Amyloid-β	Neurological Disease
AChE/Aβ-IN-2 (compound 33) is a potent and orally active inhibitor of acetylcholinesterase (AChE) with IC₅₀ of 135 nM, as well as an antagonist of NMDA receptor (GluN1-1b/GluN2B subunit combination) with IC₅₀ of 5.054 μM. AChE/Aβ-IN-2 also inhibits Aβ aggregation and shows good blood-brain barrier permeability. AChE/Aβ-IN-2 improves cognitive and spatial memory impairment in rats model .

Cat. No.	Product Name

HY-L041

Macrocyclic Compound Library	364 compounds
Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity. MCE offers a unique collection of 364 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.

Macrocyclic Compound Library

364 compounds

Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity.

MCE offers a unique collection of 364 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.

HY-L170

Allosteric Modulators (AMs) Compound Library	174 compounds
An emerging drug design method is based on the secondary binding site effect, where small molecule drugs are designed to bind to secondary binding sites on target biomolecules rather than primary orthomorphic sites. Successful potential drugs (known as allosteric modulators) will be able to bind to allosteric sites and remotely alter (or modify) the conformation of the main orthosteric binding sites of biological targets. Allosteric modulators (AMs) are ligands of proteins that act through binding sites different from natural (orthosteric) ligand sites. AMs are relatively small, more lipophilic, and more rigid compounds. The binding efficacy of AMs with their targets is often slightly lower. AMs are divided into positive AMs (PAMs) and negative AMs (NAMs). AMs are ideal drug targets because they can fine-tune receptor activity while preserving the spatial and temporal signal transduction characteristics of endogenous ligands, resulting in fewer targeted side effects, improved subtype selectivity, and better promotion of biased signal transduction than normal ligands. MCE designs a unique collection of 174 small allosteric modulators. It is a good tool to be used for research on metabolize, cancer and other diseases.

Allosteric Modulators (AMs) Compound Library

174 compounds

An emerging drug design method is based on the secondary binding site effect, where small molecule drugs are designed to bind to secondary binding sites on target biomolecules rather than primary orthomorphic sites. Successful potential drugs (known as allosteric modulators) will be able to bind to allosteric sites and remotely alter (or modify) the conformation of the main orthosteric binding sites of biological targets. Allosteric modulators (AMs) are ligands of proteins that act through binding sites different from natural (orthosteric) ligand sites. AMs are relatively small, more lipophilic, and more rigid compounds. The binding efficacy of AMs with their targets is often slightly lower. AMs are divided into positive AMs (PAMs) and negative AMs (NAMs). AMs are ideal drug targets because they can fine-tune receptor activity while preserving the spatial and temporal signal transduction characteristics of endogenous ligands, resulting in fewer targeted side effects, improved subtype selectivity, and better promotion of biased signal transduction than normal ligands.

MCE designs a unique collection of 174 small allosteric modulators. It is a good tool to be used for research on metabolize, cancer and other diseases.

Cat. No.	Product Name	Type

HY-D0175

3-Aminopropyltriethoxysilane γ-Aminopropyltriethoxysilane; APTES	Biochemical Assay Reagents
3-Aminopropyltriethoxysilane (APTES) acts as a strong glue to immobilize biomolecules such as antibodies and enzymes to silicon and silicon derivatives such as silicon nitride (Si₃N₄)) on. 3-Aminopropyltriethoxysilane also acts as a spacer, providing biomolecules with more spatial freedom during immobilization for higher specific activity. 3-Aminopropyltriethoxysilane can form a more stable, sensitive, and highly biocompatible bioanalytical platform by immobilizing biomolecules onto some solid materials, electrode materials, nanomaterials, and nanocomposites .

3-Aminopropyltriethoxysilane

γ-Aminopropyltriethoxysilane; APTES

Biochemical Assay Reagents

3-Aminopropyltriethoxysilane (APTES) acts as a strong glue to immobilize biomolecules such as antibodies and enzymes to silicon and silicon derivatives such as silicon nitride (Si₃N₄)) on. 3-Aminopropyltriethoxysilane also acts as a spacer, providing biomolecules with more spatial freedom during immobilization for higher specific activity. 3-Aminopropyltriethoxysilane can form a more stable, sensitive, and highly biocompatible bioanalytical platform by immobilizing biomolecules onto some solid materials, electrode materials, nanomaterials, and nanocomposites .

Cat. No.	Product Name	Target	Research Area

HY-P2259

TAT-GluA2 3Y	iGluR	Neurological Disease
TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .

HY-P2004

FFAGLDD	MMP	Cancer
FFAGLDD is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

HY-P2004A

FFAGLDD TFA	MMP	Cancer
FFAGLDD TFA is MMP9 selective cleavage peptides, which used for cytosolic delivery of Doxorubi-cin (DOX) and achieve temporally and spatially controlled slow drug delivery and release .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0204

Pulchinenoside A Anemoside A3	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Ranunculaceae Other Diseases Plants Disease Research Fields Pulsatilla chinensis (Bunge) Regel	iGluR
Pulchinenoside A is a natural triterpenoid saponin that enhances synaptic plasticity in the adult mouse hippocampus and facilitates spatial memory in adult mice.

Cat. No.	Product Name		Classification

HY-129084

Propargylcholine bromide		Alkynes
Propargylcholine bromide is a choline analogue containing terminal propargyl that can be incorporated into all classes of Choline-containing phospholipids such as phosphatidylcholine and sphingomyelin, labeling Choline-containing phospholipids. Propargylcholine bromide-labeled phospholipid molecules can be visualized in cells with high sensitivity and spatial resolution. Propargylcholine bromide can be used as a molecular tool to study the biochemical and metabolic processes of Choline-containing phospholipids in cells . Propargylcholine (bromide) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Click Chemistry

spatial

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

NaturalProducts

Click Chemistry

Natural
Products